Please login to the form below

Not currently logged in
Email:
Password:

India revokes patent on Merck asthma drug

Cipla breaks one more of the pharma company's patents

Merck and Co - US headquartersCipla has succeeding in breaking another Indian patent held by Merck & Co, this time persuading the national patent office to revoke protection for a combination asthma drug.

The patent - covering an aerosol suspension formulation of the corticosteroid mometasone furoate and long-acting beta agonist formoterol fumarate - was awarded in March 2011 and almost immediately opposed by Cipla, which is a major supplier of generic respiratory medicines in India.

On December 10 India's Intellectual Property Appellate Board (IPAB) revoked the patent on the grounds that the combination was known and there was no inventive step in the claimed formulation, which replaced chlorofluorocarbon (CFC) propellants with more environmentally-friendly hydrofluoroalkanes (HFAs).

The patent was originally filed in 2004 by Schering-Plough, which was acquired by Merck in 2009 for around $41bn. The company currently markets the mometasone furoate/formoterol fumarate combination in the US as Dulera, but withdrew its bid for a European licence in 2010.

While the product covered by the patent is a minor one, the text of the decision makes reference to a number of intellectual property (IP) strategies adopted by multinational pharma companies for combination respiratory medicines, so could be cited in future cases involving asthma or chronic obstructive pulmonary disease (COPD) drugs. 

The move is the latest in a series of defeats for brand-name drug manufacturers in India. Last month, the IPAB revoked a patent on Roche's hepatitis C drug Pegasys (peginterferon alfa-2a) on the grounds of 'obviousness' and because Roche had failed to show it was more efficacious than its older, non-pegylated version of the drug.

That case followed the revocation of Pfizer's patent on cancer drug Sutent (sunitinib), as well as Bayer's failure to overturn a compulsory license which removed patent protection for its Nexavar (sorafenib) product. Roche also lost a four-year legal dispute with Cipla over patent rights to Tarceva (erlotinib) earlier this year.

Meanwhile, Cipla has a history of taking on and breaking Merck patents in India. Earlier this year the company filed a bid to secure a compulsory license for the multinational's HIV drug Isentress (raltegravir) on the grounds that the integrase inhibitor "is not available in the market at reasonable and affordable price".

12th December 2012

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics